Formulary assessment – Clascoterone 10 mg/g cream
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Clascoterone for the treatment of acne vulgaris
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. The aim of this publication is to evaluate the efficacy, safety and potential place in therapy of Clascoterone cream a first-in-class androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making
Medicines value tracker – Shower and Bath emollients; opportunity savings realised
The purpose of the Medicines value bulletin tracker publications are to support ICBs in monitoring progress and identifying remaining potential opportunity savings, for the Medicines value opportunities already identified in the RDTC Medicines Value Bulletin series. The MVB tracker publications for shower and bath emollients cover all 7 ICBs across the North of England. Please select the appropriate version for your region below.
Budget impact of emollient bath and shower preparations
The purpose of this bulletin is to promote cost effective prescribing by highlighting the lack of evidence on the efficacy of emollient bath and shower preparations for the management of atopic eczema, in line with updated NICE guidance. It considers the potential savings that could be achieved with reduced prescribing of these products across the ICSs in the North East & Yorkshire region and Greater Manchester.
This publication was updated in April 2025 – First published in February 2023
Formulary assessment – Tacalcitol (Curatoderm) Lotion and Ointment
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Formulary assessment – Trifarotene (Aklief)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Formulary assessment – tirbanibulin (Klisyri)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Pentosan for the treatment of bladder pain syndrome
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Pentosan polysulfate sodium capsules (Elmiron®, Consilient Health) are indicated for the treatment of bladder pain syndrome characterised by glomerulations or Hunner’s lesions.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
Download the full review below to read more.